Sarepta Therapeutics, Inc. (SRPT)

Market Cap	1.77B -82.9%
Revenue (ttm)	2.20B +15.6%
Net Income	-713.41M
EPS	-7.13
Shares Out	104.99M
PE Ratio	n/a
Forward PE	5.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,425,597
Open	16.65
Previous Close	16.66
Day's Range	16.65 - 17.33
52-Week Range	10.42 - 103.32
Beta	0.46
Analysts	Hold
Price Target	25.76 (+52.97%)
Earnings Date	May 5, 2026

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 1997
• Employees: 835
• Stock Exchange: NASDAQ
• Ticker Symbol: SRPT
• Website: https://www.sarepta.com

Analyst Summary

According to 28 analysts, the average rating for SRPT stock is "Hold." The 12-month stock price target is $25.76, which is an increase of 52.97% from the latest price.

Price Target

$25.76

(52.97% upside)

Analyst Consensus: Hold